DISOPYRAMIDE phosphate (Norpace) has been used extensively for more than 10 years to treat atrial and ventricular arrhythmias;'-9 it has been approved in the United States for treatment of ventricular arrhythmias. As a class I antiarrhythmic agent, it decreases the amplitude and maximum upstroke velocity of the transmembrane action potential, prolongs its duration and slows the rate of rise of phase 41 0 Like other class I agents, it prolongs infranodal conduction time, although this does not appear to be clinically important when blood disopyramide levels are in the therapeutic range. i" The use of disopyramide in patients with firstdegree or type I atrioventricular (AV) block and narrow QRS is not advised without suitable precautions,12 although in no previous studies have drug safety and efficacy been assessed. Previous studies in other patient populations have revealed a variable effect of disopyramide on AV nodal conduction and refractoriness, and this has been ascribed to the interplay of its membrane-depressant and anticholinergic actions. '3- In the present study, we assessed the electrophysiologic effects and safety of i.v. disopyramide in patients with AV nodal dysfunction.
Methods
Patients entered into the study had been referred for electrophysiologic evaluation because of symptoms suggesting higher grades of AV block and surface electrocardiographic findings of first-degree (PR > 0.2 second) or Mobitz I (Wenckebach) AV block. These findings were confirmed in all patients during at least one 24-hour Holter recording. Patients were excluded if they had uncompensated cardiac failure, Mobitz II or third-degree AV block, renal impairment (serum creatinine > 2 mg/ml), myocardial infarction within the previous 4 months, a systolic blood pressure of less than 100 mm Hg or bundle branch block. The study was performed with the approval of the Committee on Human Research of the University of California, San Francisco, and each patient gave fully informed consent. The studies were performed at the University of California, San Francisco, and the Veterans Administration Medical Center, Fresno.
The patients were studied after having stopped all antiarrhythmic medications for four elimination drug half-lives. One to three surface ECG leads were recorded.
Two quadripolar pacing catheters were inserted via a femoral vein. One was advanced to the high right atrium and the other just across the tricuspid valve. The control sinus cycle length (CL) and AV nodal (AH) and infranodal (HQ) conduction times were measured. 16 The mean disopyramide level at the conclusion of repeat electrophysiologic testing was 2.9 + 0.9 ug/ ml. Because the therapeutic range for disopyramide is considered to be 2.0-4.0 ,ug/ml, only two patients (nos. 4 and 5) had subtherapeutic blood levels of disopyramide at the time of repeat study; blood levels were not available in patient 2. oral therapy. In two of the five patients, chronic therapy was discontinued because of the development of signs and symptoms of congestive heart failure 4 days and 2 weeks, respectively, after initiation of oral disopyramide. Both of these patients had a history of congestive heart failure but were well compensated at the time of study. control recordings that reverted to 1:1 conduction after disopyramide ( fig. 3) 19 included three patients with first-degree AV block in their study of 10 patients with cardiac disease and found no change in AV nodal conduction or refractoriness. However, the disopyramide levels that they achieved were almost always < 2 ,ug/ml, which is below the accepted minimal therapeutic blood level. The most likely explanation for the varied effects of disopyramide on AV nodal conduction and refractoriness relates to the interplay between direct and vagolytic actions of this drug on AV nodal function. 18 In contrast to the varied effects of this drug on antegrade AV conduction, retrograde ventriculoatrial conduction showed definite deterioration. The exact size of retrograde block could not be determined because the His bundle deflection could not be recorded during ventricular pacing. However, our findings are similar to those of Shenasa et al.,20 who described varying effects on antegrade but impaired retrograde AV nodal conduction after procainamide in patients without supraventricular tachycardia. Our findings are in accord with those of Swiryn et al.,21 who found uniform depression of ventriculoatrial conduction in patients with either AV nodal or AV reentrant tachycardia after treatment with oral disopyramide. In contrast to our study (and to other studies of patients without PSVT), they also found uniform depression of antegrade AV nodal conduction. The differences may be related to differing AV nodal responses to this drug in patients with paroxysmal supraventricular tachycardia. In addition, we administered i.v. disopyramide, while Swiryn et al. restudied the patients after oral disopyramide. The latter approach could result in more direct suppression of antegrade AV nodal conduction.
Our study also emphasizes the limitations in the use of changes in the PR interval as a reflection of AV nodal function in patients treated with disopyramide. Patient 11, for example, showed marked increases in the AH interval after disopyramide without significant changes in AV nodal conduction or refractoriness. In addition, dysopyramide usually prolongs infranodal conduction and, hence, may lengthen the PR interval without affecting AV nodal function.
Our findings suggest that i.v. disopyramide may be safely administered to patients with AV nodal disease manifested by first-degree or type I AV block and narrow QRS complexes. The safety of chronic oral disopyramide must be tested in further clinical trials. Our preliminary data in five patients treated with chronic oral disopyramide suggest that the i.v. effects on AV conduction predict subsequent effects of shortterm oral therapy. In contrast, although none of the patients showed obvious adverse hemodynamic effects during or after i.v. disopyramide, two developed signs and symptoms of congestive heart failure while on chronic oral therapy, suggesting that the hemodynamic response to i.v. administration may not predict the chronic oral response.
These findings should not be extrapolated to include patients with bundle branch block, because first-degree AV block or type I AV block may result from infranodal block. Finally, our study population had normal or minimally impaired cardiac function and the serum electrolytes were within normal limits. Our findings, therefore, cannot be extrapolated to seriously ill or unstable cardiac patients. DISOPYRAMIDE is a useful antiarrhythmic agent that has significant effects against a variety of experimental" 2 and clinical3'-arrhythmias of both atrial and ventricular origin. Its spectrum of antiarrhythmic effects is similar to that of quinidine in rabbit right atria,' canine Purkinje fibers"1' and in the specialized conduction system in man.'2 13 However, the mechanisms of electrophysiologic action of disopyramide on sinus node function in man are controversial.""'6 Birkhead and Vaughan Williams'5 suggested that disopyramide has dual effects on sinus nodal automaticity, resulting in a potentially un-predictable effect on sinus node function. One effect was thought to be mediated by a direct depressant action of the drug on sinus node cells, causing a slowing of heart rate, and the other action to be mediated by disopyramide's anticholinergic action (that is, atropine-like action), which would remove cholinergic inhibitory action, causing an acceleration of heart rate. These properties of disopyramide could similarly affect in a dual manner the sinus node recovery time. Therefore, the purpose of the present study was to test the hypothesis that disopyramide has dual actions on sinus nodal automaticity, and, if so, to determine the cellular mechanisms of the dual action. We used standard microelectrode techniques to record transmembrane potentials using isolated rabbit right atrial preparations before and after superfusion with disopyramide, under control (resting), activated and blocked cholinergic tone to determine the cellular electrophysiologic mechanisms of disopyramide's actions on the sinus nodal pacemaker cells.
Rabbits that weighed 1.5-3 kg were stunned by a blow on the head. The hearts were then rapidly excised and dissected in cool, oxygenated, modified Tyrode's
